Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TransCode Therapeutics ( (RNAZ) ) just unveiled an announcement.
On February 23, 2026, TransCode Therapeutics announced the publication of a preclinical manuscript in Molecular Imaging and Biology detailing a novel tumor-selective RIG-I agonist strategy. The study, published February 19, 2026, shows how overexpressed oncogenic microRNAs, such as miRNA-21, can be used as intracellular templates to activate innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery.
The work, conducted with Michigan State University’s Dr. Anna Moore, suggests this template-driven approach may mitigate long-standing issues with RIG-I agonists, including off-target immune activation and inefficient systemic delivery. By integrating this strategy with TransCode’s TTX nanoparticle platform, currently in clinical evaluation, the data support the translational potential of a more precise, image-guided cancer immunotherapy that could enhance the company’s positioning in RNA-based oncology.
The most recent analyst rating on (RNAZ) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, and its broader portfolio focuses on first-in-class therapies designed to mobilize the immune system against cancer cells.
The company operates in the cancer therapeutics market with a focus on leveraging RNA biology and nanoparticle delivery platforms to create targeted treatments. TransCode’s pipeline and technology aim to address unmet medical needs in metastatic and difficult-to-treat cancers, positioning it among emerging players in RNA-based oncology.
Average Trading Volume: 263,810
Technical Sentiment Signal: Sell
Current Market Cap: $8.44M
Learn more about RNAZ stock on TipRanks’ Stock Analysis page.